Nevirapine, given once during labor, either alone or in combination with a short course of zidovudine (AZT) or other antiretroviral medications, significantly reduces the chances that a pregnant woman will pass HIV to her child. A single dose of nevirapine during labor is frequently all that is accessible to pregnant women in resource-limited settings where more complicated and expensive, multidrug treatments may not be available.
The use of single-dose nevirapine has successfully reduced mother-to-infant transmission of HIV, but has also created a terrible dilemma for physicians and patients. Research has shown that 20 to 69 percent of women who take a single dose of nevirapine during labor subsequently develop resistance to the drug -- a situation that may undermine the patients" ability to respond later to nevirapine-containing ART when they may need the treatment to save their lives. Nevirapine is the cornerstone of three-drug ART in most regions of the world. Drug resistance develops as well in a range of the minority of infants who become HIV infected, despite the use of single-dose nevirapine.
Now, a team of researchers led by Shahin Lockman, Assistant Professor in the Department of Immunology and Infectious Diseases at Harvard School of Public Health (HSPH) and at Brigham and Women's Hospital, and Max Essex, chair of the HSPH AIDS Initiative, has conducted a study that suggests a potential solution to this problem. The results may help women who already received a single dose of nevirapine during labor and those who have not yet given birth.
Working within a randomized clinical trial established by the Botswana-HSPH AIDS Initiative Partnership for HIV Research and Education, the team conducted a prospective observational study that included 218 postpartum, HIV-infected women who had received a single dose of nevirapine during labor, in addition to a short course of AZT during pregnancy. Sixty women started nevirapine-based ART within six months of giving birth, and the remaining women began the regimen after that time had passed.
Of the 60 women who started nevirapine-based ART within six months of giving birth, 24 had received a single dose of nevirapine during labor, while 36 had received a placebo. (All of the women in the study were given zidovudine from 34 weeks into their pregnancies through delivery; similar to nevirapine, zidovudine reduces HIV transmission from mother to child.) Of the women in this group who received a single dose of nevirapine during labor, 41.7 percent subsequently experienced treatment failure, or "virologic failure," within a half a year of starting ART -- compared to zero percent among the women in this group who had received placebo during delivery. Similar differences were found at follow-up visits one and two years after ART had started.
In contrast, there were no statistically significant differences in failure rates within the women who delayed ART for six months -- regardless of whether they had received a single dose of nevirapine during labor or not. This group (and additional women who have joined the study since) continues to be followed to ensure that no differences emerge as the women receive treatment over a longer period of time, said Dr. Lockman.
She added that these findings may be explained by the fact that the amount of nevirapine-resistant HIV in the body decreases as time passes from the time of exposure to single-dose nevirapine during labor.
Said Dr. Essex, "These results translate into very clear policy for how to treat AIDS in new mothers who received nevirapine to protect their infants. If you can wait six months to administer nevirapine-based ART, do so. If not, treat only with combinations of drugs that do not contain nevirapine or nevirapine-related drugs. Implementing this policy can improve the health of women who need AIDS treatment."
Treatment response was also measured among 30 infants in the study who received nevirapine-based ART. More than three-quarters of the 15 infants who were exposed to single dose nevirapine as newborns did not respond adequately to the triple-drug treatment (compared with 9.1 percent of the 15 infants without prior nevirapine exposure). While these results raise concerns regarding the use of nevirapine-based ART for infants following single-dose nevirapine exposure, said Dr. Lockman, the group of infants studied was small, and additional data among infants is needed.
Summarized Dr. Lockman, "Women who need combination ART for their own health during pregnancy should absolutely receive combination ART whenever possible. However, single-dose nevirapine remains important in preventing mother-to-child transmission of HIV in many locales where it is still the only intervention available. This study provides some important guidance and measured reassurance regarding the timing and effectiveness of nevirapine-based antiretroviral treatment for the many women with AIDS who previously received single-dose nevirapine in labor."
Christina Roache | EurekAlert!
Correct connections are crucial
26.06.2017 | Charité - Universitätsmedizin Berlin
One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...
19.06.2017 | Event News
13.06.2017 | Event News
13.06.2017 | Event News
27.06.2017 | Earth Sciences
27.06.2017 | Earth Sciences
27.06.2017 | Life Sciences